Urging the Director of the Food and Drug Administration to reevaluate the safety of all chemical abortion drugs in light of recent independent studies, and for other purposes.

HRES 803 is a non-binding resolution urging the FDA to reassess the safety of all chemical abortion drugs based on recent independent studies. It specifically requests the FDA reevaluate safety data and publicly release a full safety review including real-world complications. The resolution does not change laws or create new requirements but asks the FDA to consider findings that claim complication rates are 22 times higher than current reports. This resolution directly addresses the FDA's regulatory oversight of these drugs, not other entities or policies.